Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer

BACKGROUND It has recently been reported that metastases of prostate cancer usually show highly heterogeneous or partly lost prostate-specific membrane antigen (PSMA) expression. In order to image and treat both PSMA positive and negative tissues PSMA targeting probes need to be extended by a furthe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Eder, Matthias (VerfasserIn) , Schäfer, Martin (VerfasserIn) , Bauder‐Wüst, Ulrike (VerfasserIn) , Haberkorn, Uwe (VerfasserIn) , Eisenhut, Michael (VerfasserIn) , Kopka, Klaus (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 25 January 2014
In: The prostate
Year: 2014, Jahrgang: 74, Heft: 6, Pages: 659-668
ISSN:1097-0045
DOI:10.1002/pros.22784
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/pros.22784
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.22784
Volltext
Verfasserangaben:Matthias Eder, Martin Schäfer, Ulrike Bauder‐Wüst, Uwe Haberkorn, Michael Eisenhut, and Klaus Kopka

MARC

LEADER 00000caa a2200000 c 4500
001 1728628539
003 DE-627
005 20230428032957.0
007 cr uuu---uuuuu
008 200902s2014 xx |||||o 00| ||eng c
024 7 |a 10.1002/pros.22784  |2 doi 
035 |a (DE-627)1728628539 
035 |a (DE-599)KXP1728628539 
035 |a (OCoLC)1341358376 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Eder, Matthias  |d 1979-  |e VerfasserIn  |0 (DE-588)140263217  |0 (DE-627)616969279  |0 (DE-576)316151092  |4 aut 
245 1 0 |a Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer  |c Matthias Eder, Martin Schäfer, Ulrike Bauder‐Wüst, Uwe Haberkorn, Michael Eisenhut, and Klaus Kopka 
264 1 |c 25 January 2014 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.09.2020 
520 |a BACKGROUND It has recently been reported that metastases of prostate cancer usually show highly heterogeneous or partly lost prostate-specific membrane antigen (PSMA) expression. In order to image and treat both PSMA positive and negative tissues PSMA targeting probes need to be extended by a further specificity. Since prostate cancer cells usually express both PSMA and gastrin-releasing peptide receptor (GRPR) a bispecific low-molecular heterodimeric molecule, addressing both targets at the same time, may significantly improve prostate cancer imaging and therapy. METHODS The nonapeptide BZH3 representing the GRPR binding part was combined with the urea-based PSMA inhibitor Glu-urea-Lys(Ahx)-HBED-CC. The syntheses of the compounds were performed according to standard Fmoc-solid phase peptide synthesis. The binding properties were analyzed by competitive cell binding and internalization experiments. The in vivo targeting properties were investigated by means of biodistribution studies. RESULTS Cell binding experiments revealed high binding affinities to both GRPR and PSMA expressing cell lines. The heterodimer bound with IC50-values essentially matching the IC50 values of the respective monomers (25.0 ± 5.4 nM for PSMA and 9.0 ± 1.8 nM for GRPR, respectively). In vivo, the heterodimer showed dual targeting of PSMA (5.4%ID/g for PSMA-positive tumors) and GRPR receptors (3.3% ID/g for GRPR-positive tumors) while exhibiting fast pharmacokinetic properties. The clearance from background was comparable to the monomeric PSMA-targeting reference. CONCLUSIONS The heterodimeric molecule is a promising agent for PET imaging of primary and recurrent prostate cancer covering two receptor entities which might lead to an improved diagnostic sensitivity and therapeutic efficiency. Prostate 74:659-668, 2014. © 2014 The Authors. The Prostate published byWiley Periodicals, Inc. 
650 4 |a bispecific PET imaging 
650 4 |a heterodimeric radiopharmaceuticals 
650 4 |a prostate cancer 
650 4 |a tumor heterogeneity 
700 1 |a Schäfer, Martin  |e VerfasserIn  |4 aut 
700 1 |a Bauder‐Wüst, Ulrike  |e VerfasserIn  |4 aut 
700 1 |a Haberkorn, Uwe  |d 1959-  |e VerfasserIn  |0 (DE-588)1022913905  |0 (DE-627)717331245  |0 (DE-576)366166352  |4 aut 
700 1 |a Eisenhut, Michael  |e VerfasserIn  |0 (DE-588)1113306122  |0 (DE-627)867174501  |0 (DE-576)160846080  |4 aut 
700 1 |a Kopka, Klaus  |d 1968-  |e VerfasserIn  |0 (DE-588)173031862  |0 (DE-627)69795661X  |0 (DE-576)133884724  |4 aut 
773 0 8 |i Enthalten in  |t The prostate  |d New York, NY : Wiley-Liss, 1980  |g 74(2014), 6, Seite 659-668  |h Online-Ressource  |w (DE-627)303391634  |w (DE-600)1494709-2  |w (DE-576)088704998  |x 1097-0045  |7 nnas  |a Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer 
773 1 8 |g volume:74  |g year:2014  |g number:6  |g pages:659-668  |g extent:10  |a Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer 
856 4 0 |u https://doi.org/10.1002/pros.22784  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.22784  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200902 
993 |a Article 
994 |a 2014 
998 |g 173031862  |a Kopka, Klaus  |m 173031862:Kopka, Klaus  |p 6  |y j 
998 |g 1113306122  |a Eisenhut, Michael  |m 1113306122:Eisenhut, Michael  |d 50000  |e 50000PE1113306122  |k 0/50000/  |p 5 
998 |g 1022913905  |a Haberkorn, Uwe  |m 1022913905:Haberkorn, Uwe  |d 910000  |d 911400  |e 910000PH1022913905  |e 911400PH1022913905  |k 0/910000/  |k 1/910000/911400/  |p 4 
998 |g 140263217  |a Eder, Matthias  |m 140263217:Eder, Matthias  |d 50000  |e 50000PE140263217  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1728628539  |e 3746078210 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Matthias","family":"Eder","display":"Eder, Matthias","role":"aut"},{"display":"Schäfer, Martin","given":"Martin","family":"Schäfer","role":"aut"},{"display":"Bauder‐Wüst, Ulrike","given":"Ulrike","family":"Bauder‐Wüst","role":"aut"},{"family":"Haberkorn","given":"Uwe","display":"Haberkorn, Uwe","role":"aut"},{"display":"Eisenhut, Michael","family":"Eisenhut","given":"Michael","role":"aut"},{"role":"aut","display":"Kopka, Klaus","family":"Kopka","given":"Klaus"}],"title":[{"title":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer","title_sort":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer"}],"origin":[{"dateIssuedKey":"2014","dateIssuedDisp":"25 January 2014"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 02.09.2020"],"recId":"1728628539","id":{"eki":["1728628539"],"doi":["10.1002/pros.22784"]},"name":{"displayForm":["Matthias Eder, Martin Schäfer, Ulrike Bauder‐Wüst, Uwe Haberkorn, Michael Eisenhut, and Klaus Kopka"]},"relHost":[{"note":["Gesehen am 28.02.08"],"title":[{"title_sort":"prostate","title":"The prostate"}],"pubHistory":["1.1980 -"],"origin":[{"publisher":"Wiley-Liss","dateIssuedDisp":"1980-","publisherPlace":"New York, NY","dateIssuedKey":"1980"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancerThe prostate","physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"74(2014), 6, Seite 659-668","issue":"6","year":"2014","extent":"10","pages":"659-668","volume":"74"},"language":["eng"],"recId":"303391634","id":{"doi":["10.1002/(ISSN)1097-0045"],"zdb":["1494709-2"],"issn":["1097-0045"],"eki":["303391634"]}}],"physDesc":[{"extent":"10 S."}],"language":["eng"]} 
SRT |a EDERMATTHIPRECLINICA2520